TCAs may leads to higher number of dropouts due to adverse effects compared with benzodiazepines (low certainty).
It is very uncertain whether SSRIs changes failure to respond compared with benzodiazepines (very low certainty).
It is very uncertain whether SSRIs changes total number of dropouts compared with benzodiazepines (very low certainty).
It is very uncertain whether SSRIs changes failure to remit compared with benzodiazepines (very low certainty).
It is very uncertain whether SSRIs changes number of dropouts due to adverse effects compared with benzodiazepines (very low certainty).
It is very uncertain whether antidepressants changes total number of dropouts compared with benzodiazepines (very low certainty).
Antidepressants probably leads to higher failure to remit compared with benzodiazepines (moderate certainty).
Antidepressants may leads to higher number of dropouts due to adverse effects compared with benzodiazepines (low certainty).
It is very uncertain whether TCAs changes failure to respond compared with benzodiazepines (very low certainty).
It is very uncertain whether TCAs changes total number of dropouts compared with benzodiazepines (very low certainty).
TCAs showed no clear difference in failure to remit compared with benzodiazepines (moderate certainty).
It is very uncertain whether all psychological therapies changes short‐term remission compared with benzodiazepines (very low certainty).
It is very uncertain whether all psychological therapies changes short‐term response compared with benzodiazepines (very low certainty).
It is very uncertain whether all psychological therapies changes dropouts for any reason compared with benzodiazepines (very low certainty).
All psychological therapies showed no clear difference in short‐term remission compared with antidepressants alone or antidepressants and benzodiazepines (low certainty).